WebGet the latest Salarius Pharmaceuticals Inc (SLRX) real-time quote, historical performance, charts, and other financial information to help you make more informed … Web19 mrt. 2024 · Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers …
What date does Salarius Pharmaceuticals
Web20 sep. 2024 · SLRX U.S.: Nasdaq Salarius Pharmaceuticals Inc. Watch list Create SLRX Alert After Hours Last Updated: Sep 20, 2024 7:55 p.m. EDT Delayed quote $ 0.2150 … Web13 apr. 2024 · Washington Prime Group - WPG Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Compare Today's Range N/A 50-Day Range $0.81 $1.72 52-Week Range N/A Volume 1.79 million shs Average Volume 3.63 million shs Market Capitalization $20.36 million P/E … idm microsoft edge error
Salarius (SLRX) Reports Q3 Loss, Misses Revenue Estimates
Web31 mrt. 2024 · View Salarius Pharmaceuticals, Inc SLRX investment & stock information. Get the latest Salarius Pharmaceuticals, Inc SLRX detailed stock quotes, stock data, … Web13 jun. 2024 · Salarius Pharmaceuticals Inc. (NAS : SLRX) most recent headlines All News Headlines and Company Releases News Headlines for Salarius Pharmaceuticals Inc. … Web13 apr. 2024 · About SLRX Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. idmmotrix